Literature DB >> 31537272

From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes: JACC State-of-the-Art Review.

Karolina Szummer1, Tomas Jernberg2, Lars Wallentin3.   

Abstract

This focus seminar will take the reader through the history and pivotal trials that have formed the current state-of-the-art management for acute coronary syndromes. The identification of a ruptured plaque with thrombus formation and subsequent occlusion or downstream embolization in the coronary artery was the key to developing new and effective treatment strategies. The traditional wait-and-see approach with prolonged bedrest was replaced in the 1980s by immediate pharmacological reperfusion of the occluded coronary artery and long-term aspirin to prevent reinfarction. Mechanical reperfusion with percutaneous coronary intervention with stenting and more intense platelet inhibition with P2Y12 inhibitors further improved outcomes from early 2000s. Adjunctive treatment regimens, including anticoagulants, statins, and neurohormonal inhibition, were found to further reduce mortality and prevent new infarctions. Taken together, the use of new combined pharmacological and interventional treatment strategies has led to a remarkable decrease in 1-year mortality from around 22% in 1995 to around 11% by 2014.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ST-segment elevation myocardial infarction; acute coronary syndrome; antithrombotic treatment; clinical trials; myocardial infarction; non–ST-segment elevation myocardial infarction; outcomes; percutaneous coronary intervention; reperfusion treatment; revascularization

Year:  2019        PMID: 31537272     DOI: 10.1016/j.jacc.2019.03.531

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

1.  Prognostic performance of Controlling Nutritional Status score in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.

Authors:  Ahmet Zengin; Mehmet Baran Karataş; Yiğit Çanga; Gündüz Durmuş; Özge Güzelburç; Furkan Durak; Ayşe Emre
Journal:  Anatol J Cardiol       Date:  2022-01       Impact factor: 1.596

2.  Acute myocardial infarction with high Killip class: do geographic differences matter?

Authors:  Xavier Rossello; Maria F Ramis-Barceló; Sergio Raposeiras-Roubín
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2021-06-30

3.  Spotlight on comorbidities in STEMI patients.

Authors:  Raphael Romano Bruno; Malte Kelm; Christian Jung
Journal:  Endocrinol Diabetes Metab       Date:  2019-11-19

4.  Coronary Artery Bypass Graft Surgery in Patients With Acute Coronary Syndromes After Primary Percutaneous Coronary Intervention: A Current Report From the North-Rhine Westphalia Surgical Myocardial Infarction Registry.

Authors:  Matthias Thielmann; Daniel Wendt; Ingo Slottosch; Henryk Welp; Wolfgang Schiller; Konstantinos Tsagakis; Bastian Schmack; Alexander Weymann; Sven Martens; Markus Neuhäuser; Thorsten Wahlers; Yeong-Hoon Choi; Arjang Ruhparwar; Oliver-J Liakopoulos
Journal:  J Am Heart Assoc       Date:  2021-09-13       Impact factor: 5.501

5.  Development and validation of a novel risk score to predict 5-year mortality in patients with acute myocardial infarction in China: a retrospective study.

Authors:  Yan Tang; Yuanyuan Bai; Yuanyuan Chen; Xuejing Sun; Yunmin Shi; Tian He; Mengqing Jiang; Yujie Wang; Mingxing Wu; Zhiliu Peng; Suzhen Liu; Weihong Jiang; Yao Lu; Hong Yuan; Jingjing Cai
Journal:  PeerJ       Date:  2022-01-04       Impact factor: 2.984

6.  Prevalence and prognostic significance of malnutrition in patients with acute coronary syndrome treated with percutaneous coronary intervention.

Authors:  Se Hun Kang; Han Na Song; Jae Youn Moon; Sang-Hoon Kim; Jung-Hoon Sung; In Jai Kim; Sang-Wook Lim; Dong-Hun Cha; Won-Jang Kim
Journal:  Medicine (Baltimore)       Date:  2022-08-26       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.